We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...
11h
MarketBeat on MSNMerck: 4 No-Brainer Reasons to Buy This DipBig pharma has come under a lot of scrutiny from regulators and consumers as sentiment sours on the industry. As such, the ...
TD Cowen has downgraded Merck (NYSE:MRK) to hold from buy, citing Keytruda's impending loss of market exclusivity, or LOE. The bank said it no longer sees "viable arguments" for outperformance in the ...
TD Cowen had upgraded Merck in early 2024 based on confidence in Keytruda and Gardasil’s performance, a lack of binary risks, and an attractive valuation. However, setbacks in Gardasil’s China sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results